Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin add-on therapy for right ventricular failure in pulmonary hypertension
2016-001199-31Phase 2Active
- Start
- Feb 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of terlipressin in pulmonary hypertension (PH) and Right heart dysfunction (RHF) (2 arms). Primary endpoints: Change in creatinine after 48 hours, Weight loss over the first 48 hours after start of drug administration and 1 more. Started Feb 2017; status: active.
02
Drugs
terlipressin
03
Conditions
pulmonary hypertension (PH)Right heart dysfunction (RHF)
Beyond the preview
Go deeper on 2016-001199-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001199-31.